Citius Oncology Inc. Company Profile
NASDAQ: CTORHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Citius Oncology at a glance
Citius Oncology Inc. (NASDAQ: CTOR) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Cranford, NJ. Citius Oncology is led by Mr. Leonard L. Mazur. The company's shares have traded publicly since 2022.
At a market capitalization of $52.6 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001851484, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Citius Oncology do?
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
Business description based on the company's public filings.
Company information
- Legal name
- Citius Oncology Inc.
- Ticker
- NASDAQ: CTOR
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Leonard L. Mazur
- Headquarters
- 11 Commerce Drive, Cranford, NJ, United States
- Phone
- 908 967 6677
- IPO year
- 2022
- Market cap
- $52.57M
- SEC CIK
- 0001851484
- Latest annual report
- 10-K · Dec 23, 2025
Companies similar to Citius Oncology
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LFVNLifevantage Corporation | 4.15 | -15.13% | $52.63M | vs CTOR |
| XBITXBiotech Inc. | 1.73 | +2.98% | $52.74M | vs CTOR |
| XLOXilio Therapeutics Inc. | 7.56 | -1.11% | $53.40M | vs CTOR |
| ALDXAldeyra Therapeutics Inc. | 0.84 | +16.39% | $50.70M | vs CTOR |
| CLNNClene Inc. | 3.52 | +0.57% | $50.69M | vs CTOR |
| BOLDBoundless Bio Inc. | 2.32 | -2.52% | $54.78M | vs CTOR |
| AZRAzora Therapeutics Inc. | 3.85 | -0.52% | $55.00M | vs CTOR |
| ACRVAcrivon Therapeutics Inc. | 1.15 | -17.86% | $49.35M | vs CTOR |